Milestone Pharmaceuticals (MIST)

• Market cap: $148M
• 1 day: 2.96%
• 5 days: 2.35%
• 1 month: -10.31%
• 3 months: -26.58%
• 6 months: 2.96%
• Year to date: -15.12%
• 1 year: -7.94%
• 5 years: -76.49%
• 10 years: -88.68%
• Sector: Healthcare
• Industry: Biotechnology

About: Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Employees: 33